Rich Kender assembled a team to evaluate the potential profitability of Davanrik.
Senior researchers evaluated scientific aspects of the compound,
and marketers evaluated the market size,
potential competition,
and requirements to successfully launch the drug.
Meanwhile, manufacturing managers determined the capital required to produce the drug,
and people in Kender‘s own department built a financial analysis of the licensing decision.